Egetis Therapeutics Unveils Emcitate Commercial Strategy and MCT8 Deficiency Market Expansion Plans
I'm PortAI, I can summarize articles.
Egetis Therapeutics AB has announced its commercial strategy for Emcitate®, the first approved treatment for MCT8 deficiency, recently launched in Germany. The company has supplied Emcitate to over 230 patients across 25 countries and is pursuing a rolling New Drug Application with the US FDA, aiming for a complete submission in early 2026. Egetis expects a US launch later that year and is commercializing Emcitate in the EU and US while partnering in other regions. The drug has received several regulatory designations, including Breakthrough Therapy and Orphan Drug Designation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments